These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 28089229)
1. Immune checkpoint inhibition in malignant mesothelioma: Does it have a future? Mansfield AS Lung Cancer; 2017 Mar; 105():49-51. PubMed ID: 28089229 [No Abstract] [Full Text] [Related]
7. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. Lee HS; Jang HJ; Choi JM; Zhang J; de Rosen VL; Wheeler TM; Lee JS; Tu T; Jindra PT; Kerman RH; Jung SY; Kheradmand F; Sugarbaker DJ; Burt BM JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618661 [TBL] [Abstract][Full Text] [Related]
8. Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions. Wong RM J Thorac Oncol; 2016 Oct; 11(10):1602-3. PubMed ID: 27663394 [No Abstract] [Full Text] [Related]
9. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G Tumori; 2016; 102(1):18-30. PubMed ID: 26481865 [TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint blockade in malignant mesothelioma. Calabrò L; Maio M Semin Oncol; 2015 Jun; 42(3):418-22. PubMed ID: 25965359 [TBL] [Abstract][Full Text] [Related]
11. Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer? Cheng M; Durm G; Hanna N; Einhorn LH; Kong FS Future Oncol; 2017 Dec; 13(28):2503-2505. PubMed ID: 29168656 [No Abstract] [Full Text] [Related]
13. Effectiveness of Nivolumab on Sarcomatoid Malignant Pleural Mesothelioma With Eosinophilia and Eosinophilic Pleural Effusion. Yamazoe M; Ozasa H; Kim YH J Thorac Oncol; 2019 Nov; 14(11):e251-e253. PubMed ID: 31668324 [No Abstract] [Full Text] [Related]
14. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?". Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063 [TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials. Mohamed H; Eltobgy M; Abdel-Rahman O Anticancer Agents Med Chem; 2017; 17(9):1228-1233. PubMed ID: 28042777 [TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. Metaxas Y; Rivalland G; Mauti LA; Klingbiel D; Kao S; Schmid S; Nowak AK; Gautschi O; Bartnick T; Hughes BG; Bouchaab H; Rothschild SI; Pavlakis N; Wolleb S; Petrausch U; O'Byrne K; Froesch P; Löffler-Baumann M; Pratsch-Peter S; Russell P; Mingrone W; Savic S; Thapa B; Früh M; Pless M; von Moos R; John T J Thorac Oncol; 2018 Nov; 13(11):1784-1791. PubMed ID: 30142389 [TBL] [Abstract][Full Text] [Related]
17. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Shien K; Papadimitrakopoulou VA; Wistuba II Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919 [TBL] [Abstract][Full Text] [Related]
18. Malignant Mesothelioma: Time to Translate? Napolitano A; Carbone M Trends Cancer; 2016 Sep; 2(9):467-474. PubMed ID: 28603777 [TBL] [Abstract][Full Text] [Related]
19. Peripheral lymphadenopathy as the initial manifestation of malignant mesothelioma in a child. Gong YS; Rong YT; Han WC; Zhang YC Hum Pathol; 2013 Apr; 44(4):664-9. PubMed ID: 23313308 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism. Hamaidia M; Gazon H; Hoyos C; Hoffmann GB; Louis R; Duysinx B; Willems L JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31534051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]